Qualigenix codes, submits and follows up on urology claims for independent practices, ASCs and hospital-based urology departments in 48 states. Our specialty coders handle office cystoscopy, urodynamics, stone procedures, BPH treatments, robotic prostatectomy and in-office drug administration. Across our client base, claims reach a 98.2% first-pass clean claim rate on first submission.
Urology medical billing requires correct CPT and HCPCS coding across office, surgical and oncology services, global-period tracking after surgery, prior authorization for procedures and specialty drugs, and drug-waste reporting on single-dose vials. Qualigenix handles all of it with specialty coders, 98.9% coding accuracy and a 97.7% net collections rate across its client base. Book a free billing audit at 786-259-0231 to see where your urology claims are stalling.
Cystoscopy sits underneath a large share of urology codes, which creates bundling problems. Diagnostic cystoscopy (52000) is a separate procedure, so it isn't billed when a surgical cystoscopy such as a biopsy (52204) or bladder tumor resection (52234–52240) happens in the same session. Robotic prostatectomy (55866) already includes cystourethroplasty, so 51800 can't be billed with it. Missing these rules means overbilling that invites audits or underbilling that leaves payment behind.
Many commercial and Medicare Advantage plans require prior authorization for urologic surgery, neuromodulation, advanced imaging, specialty medications and oncology therapies. When a procedure goes ahead without an approved authorization, the claim is usually denied, and a retroactive approval is hard to get.
Medicare assigns most urologic surgery a global period of 0, 10 or 90 days, and routine post-op visits inside that window are already paid in the surgical fee. Revenue leaks in two directions. Practices bill routine post-op checks that get denied, or they miss services that are separately payable: a staged procedure (modifier 58), a return to the OR for a complication (78), an unrelated procedure (79) or an unrelated office visit (24).
Many urology practices buy drugs such as leuprolide for prostate cancer and BCG for bladder cancer, give them in the office, and bill the payer afterward. Payment depends on the right HCPCS J-code, billing units that match the dose given, and the JW or JZ modifier on Medicare Part B claims for single-dose containers. CMS has required the JZ modifier, which reports that no drug was discarded, since July 1, 2023. One unit error on a high-cost drug can turn a paid injection into a loss.
Many urology patients are on Medicare with a secondary plan, or on a Medicare Advantage plan with its own referral and authorization rules. If coverage, payer order and referral requirements aren't confirmed before a cystoscopy or urodynamic study, the claim comes back as an eligibility denial.
Diagnostic tests get paid when the record shows why they were done and what they found. For ultrasound, the American Urological Association (AUA) calls for a separate signed report and permanently recorded images for each billed study. Urodynamic testing is reviewed against each payer's medical-necessity policy. A test without that support is denied as not medically necessary.
Urology claims depend on modifiers: 50 for bilateral procedures, 51 for multiple procedures, 59 or XS for distinct services, and RT or LT for laterality. A missing modifier gets the second procedure denied, and an unsupported 59 draws payer scrutiny. Some pairs can't be unbundled with any modifier. Under NCCI policy, a diagnostic transrectal ultrasound (76872) and needle guidance (76942) in the same area on the same day aren't separately reportable.
Urology billing is governed by CMS and Medicare Part B rules, NCCI edits, drug-waste reporting and HIPAA privacy requirements. CPT, HCPCS and the Medicare Physician Fee Schedule change every year, so a coding habit that was right last year can produce a denial or an overpayment this year.
Qualigenix assigns urology claims to specialty coders and checks each one against the eight gaps above, in the same order. Precision on each claim produces progress in collections. These are Qualigenix results across its client base:
Our coders code from the operative note, not the procedure list alone. They apply NCCI bundling to cystoscopy code families, catch components that are already included in robotic cases, and make sure every billable service in the note reaches the claim. Charge entry runs at a 1.6% error rate.
We check authorization requirements by payer and CPT code when a procedure or drug is scheduled, submit the request with the clinical notes the payer asks for, and track it so services are approved before treatment begins.
We track each surgical patient's global window, hold routine post-op visits that are already paid, and bill qualifying services with modifier 24, 58, 78 or 79 and the documentation to support them.
We match each in-office drug to its HCPCS code, convert the dose given into billing units, add JW or JZ on Medicare single-dose drugs, and document waste. We also track what each payer pays for each drug against your acquisition cost.
Before cystoscopies, urodynamic studies and surgery, we verify active coverage, primary and secondary payer order, referral requirements and the patient's share of the cost.
We review notes for diagnostic tests and procedures before claims go out. When a note doesn't support the code, such as a missing ultrasound report, an unsigned interpretation or an operative note without laterality, we send your provider a specific query.
We work every denial by root cause. Coding and modifier errors are corrected and resubmitted, medical-necessity denials are appealed with the record, and repeat patterns go back to your front desk and providers. Qualigenix overturns 79% of denials, with an average appeal turnaround under 9 days.
Our coders work from current CPT, HCPCS and NCCI updates, and our internal audits hold a 98.6% compliance and audit pass rate. All billing work runs on HIPAA-compliant systems.
A 3-provider podiatry group with roughly 60% Medicare payer mix carried $412,000 in A/R, 38% of it past 120 days. Routine foot care claims (11720, 11721, 11055–11057) had stalled on inconsistent Q7/Q8/Q9 modifiers and class-finding documentation, so payers held or partially paid and nobody worked the remainder. Medicare crossover to secondaries was not being posted, and small patient balances were written off.
We ran a full A/R aging segmentation, worked claims by payer and denial reason rather than by date, rebilled the stalled routine-care claims with corrected modifiers, and reactivated secondary and crossover billing.
A solo podiatrist coding 320 encounters a month was stuck at 82% first-pass acceptance. Routine foot care went out without the systemic-condition diagnosis pairing and class findings Medicare requires, so it read as non-covered. Wound debridement was coded to the wrong depth (11042 for skin and subcutaneous where the note supported 11043 for muscle and fascia). Same-day E/M with a procedure went out without modifier 25 and got bundled.
We rebuilt the coding workflow: diagnosis-to-CPT pairing rules for at-risk foot care, correct Q-modifier logic, depth-based debridement coding tied to the operative note, and disciplined use of modifiers 25 and 59/XS.
A 2-location podiatry practice sat at a 19% denial rate, mostly Medicare routine-foot-care and nail-debridement rejections. The denials clustered in three buckets: medical-necessity rejections on routine foot care (missing qualifying diagnosis and class findings), frequency-edit denials on nail debridement billed inside the 60-day window, and missing Q modifiers that flagged services as non-covered.
We built a front-end denial-prevention layer, checking eligibility and coverage against payer LCDs before claims went out, plus a structured appeal workflow with documentation templates mapped to each denial reason.
Diagnostic cystoscopy, cystoscopy with biopsy, and fulguration or resection of bladder tumors, coded by tumor size as the code family requires.
Qualigenix provides medical billing for urology organizations of every size: General urology practices Urologic oncology centers Kidney stone treatment centers Men's health clinics Robotic surgery programs Multi-specialty urology groups Hospital-based urology departments Ambulatory surgery centers (ASCs)
Qualigenix keeps urology billing compliant by coding from the operative and procedure notes, following NCCI bundling and Medicare global-period rules as written, and reporting drug waste with the JW or JZ modifier on Medicare Part B single-dose drugs. Each claim is checked against current CPT, HCPCS and NCCI updates before it's submitted. We hold a 98.6% compliance and audit pass rate, and our over- and undercoding rate stays under 2%. All billing work runs on HIPAA-compliant systems.
Cost depends on your claim volume, number of providers, payer mix and the services you need. Qualigenix quotes after a free billing audit of your current claims, which also shows where revenue is being lost. Call 786-259-0231 to start.
Yes. Our urology coders apply NCCI bundling rules to cystoscopy code families, code bladder tumor resection by tumor size, and report ureteroscopy with lithotripsy and stent placement under the correct combined code. Qualigenix holds 98.9% coding accuracy.
We code from current CPT, HCPCS and NCCI updates, document drug waste as CMS requires, and audit our own work. Qualigenix holds a 98.6% compliance and audit pass rate, and all work runs on HIPAA-compliant systems.
Yes. We work existing claims by age and balance, appeal recoverable denials and close out what can't be collected. For Qualigenix clients, days in A/R have dropped from 54 to 36. Most practices start with a free AR review.
We track the 0, 10 or 90-day global window for each surgical patient, hold routine post-op visits that are already paid, and bill qualifying services with modifier 24, 58, 78 or 79 and supporting documentation. Most practices start with a free review of their post-op claims.
Yes. We bill buy-and-bill drugs with the correct HCPCS code and billing units, add the JW or JZ modifier on Medicare Part B single-dose drugs, and report the matching administration code. We also track drug payments against your acquisition cost.
Yes. Qualigenix is system-agnostic and has worked across 133 EMR/EHR platforms, so we bill from the system you already use.